Literature DB >> 24193664

Loss of P2Y₂ nucleotide receptors enhances early pathology in the TgCRND8 mouse model of Alzheimer's disease.

Deepa Ajit1, Lucas T Woods, Jean M Camden, Christina N Thebeau, Farid G El-Sayed, Glen W Greeson, Laurie Erb, Michael J Petris, Douglas C Miller, Grace Y Sun, Gary A Weisman.   

Abstract

Neuroinflammation is a prominent feature in Alzheimer's disease (AD) and activation of the brain's innate immune system, particularly microglia, has been postulated to both retard and accelerate AD progression. Recent studies indicate that the G protein-coupled P2Y2 nucleotide receptor (P2Y2R) is an important regulator of innate immunity by assisting in the recruitment of monocytes to injured tissue, neutrophils to bacterial infections and eosinophils to allergen-infected lungs. In this study, we investigated the role of the P2Y2R in progression of an AD-like phenotype in the TgCRND8 mouse model that expresses Swedish and Indiana mutations in amyloid precursor protein (APP). Our results indicate that P2Y 2 R expression is upregulated in TgCRND8 mouse brain within 10 weeks of age and then decreases after 25 weeks of age, as compared to littermate controls expressing low levels of the P2Y 2 R. TgCRND8 mice with homozygous P2Y 2 R deletion survive less than 5 weeks, whereas mice with heterozygous P2Y 2 R deletion survive for 12 weeks, a time point when TgCRND8 mice are fully viable. Heterozygous P2Y 2 R deletion in TgCRND8 mice increased β-amyloid (Aβ) plaque load and soluble Aβ1-42 levels in the cerebral cortex and hippocampus, decreased the expression of the microglial marker CD11b in these brain regions and caused neurological deficits within 10 weeks of age, as compared to age-matched TgCRND8 mice. These findings suggest that the P2Y2R is important for the recruitment and activation of microglial cells in the TgCRND8 mouse brain and that the P2Y2R may regulate neuroprotective mechanisms through microglia-mediated clearance of Aβ that when lost can accelerate the onset of an AD-like phenotype in the TgCRND8 mouse.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24193664      PMCID: PMC3954904          DOI: 10.1007/s12035-013-8577-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  88 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

Review 2.  Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins.

Authors:  M Griffiths; J W Neal; P Gasque
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

Review 3.  ATP: a ubiquitous gliotransmitter integrating neuron-glial networks.

Authors:  Arthur M Butt
Journal:  Semin Cell Dev Biol       Date:  2011-03-03       Impact factor: 7.727

4.  Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network.

Authors:  D M Skovronsky; D B Moore; M E Milla; R W Doms; V M Lee
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

5.  P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing.

Authors:  Jean M Camden; Ann M Schrader; Ryan E Camden; Fernando A González; Laurie Erb; Cheikh I Seye; Gary A Weisman
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

6.  P2Y2 nucleotide receptor up-regulation in submandibular gland cells from the NOD.B10 mouse model of Sjögren's syndrome.

Authors:  Ann M Schrader; Jean M Camden; Gary A Weisman
Journal:  Arch Oral Biol       Date:  2004-12-15       Impact factor: 2.633

7.  Measurement of altered AβPP isoform expression in frontal cortex of patients with Alzheimer's disease by absolute quantification real-time PCR.

Authors:  William G Tharp; Yong-Ho Lee; Shane M Greene; Elise Vincellete; Thomas G Beach; Richard E Pratley
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

8.  Nucleotides released from Aβ₁₋₄₂ -treated microglial cells increase cell migration and Aβ₁₋₄₂ uptake through P2Y₂ receptor activation.

Authors:  Hye Jung Kim; Deepa Ajit; Troy S Peterson; Yanfang Wang; Jean M Camden; W Gibson Wood; Grace Y Sun; Laurie Erb; Michael Petris; Gary A Weisman
Journal:  J Neurochem       Date:  2012-03-14       Impact factor: 5.372

9.  The P2Y2 nucleotide receptor requires interaction with alpha v integrins to access and activate G12.

Authors:  Zhongji Liao; Cheikh I Seye; Gary A Weisman; Laurie Erb
Journal:  J Cell Sci       Date:  2007-05-01       Impact factor: 5.285

10.  Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein.

Authors:  M F Knauer; B Soreghan; D Burdick; J Kosmoski; C G Glabe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

View more
  24 in total

Review 1.  Supportive or detrimental roles of P2Y receptors in brain pathology?--The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies.

Authors:  Daniel Förster; Georg Reiser
Journal:  Purinergic Signal       Date:  2015-09-25       Impact factor: 3.765

Review 2.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

3.  Exercise training ameliorates cerebrovascular dysfunction in a murine model of Alzheimer's disease: role of the P2Y2 receptor and endoplasmic reticulum stress.

Authors:  Junyoung Hong; Soon-Gook Hong; Jonghae Lee; Joon-Young Park; Jason L Eriksen; Bridgette V Rooney; Yoonjung Park
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-05-08       Impact factor: 4.733

Review 4.  Therapeutic potential for P2Y2 receptor antagonism.

Authors:  Kimberly J Jasmer; Kevin Muñoz Forti; Lucas T Woods; Seunghee Cha; Gary A Weisman
Journal:  Purinergic Signal       Date:  2022-10-11       Impact factor: 3.950

Review 5.  P2Y receptors in Alzheimer's disease.

Authors:  Laurie Erb; Chen Cao; Deepa Ajit; Gary A Weisman
Journal:  Biol Cell       Date:  2014-10-13       Impact factor: 4.458

6.  Microglial P2 Purinergic Receptor and Immunomodulatory Gene Transcripts Vary By Region, Sex, and Age in the Healthy Mouse CNS.

Authors:  Jessica M Crain; Jyoti J Watters
Journal:  Transcr Open Access       Date:  2015-12-28

Review 7.  Glial Purinergic Signaling in Neurodegeneration.

Authors:  Marie J Pietrowski; Amr Ahmed Gabr; Stanislav Kozlov; David Blum; Annett Halle; Kevin Carvalho
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

Review 8.  The role of efferocytosis in neuro-degenerative diseases.

Authors:  Forough Taheri; Eskandar Taghizadeh; Jamshid Gholizadeh Navashenaq; Mehdi Rezaee; Seyed Mohammad Gheibihayat
Journal:  Neurol Sci       Date:  2022-01-21       Impact factor: 3.307

9.  The P2Y2 Receptor Interacts with VE-Cadherin and VEGF Receptor-2 to Regulate Rac1 Activity in Endothelial Cells.

Authors:  Zhongji Liao; Chen Cao; Jianjie Wang; Virginia H Huxley; Olga Baker; Gary A Weisman; Laurie Erb
Journal:  J Biomed Sci Eng       Date:  2014-12-01

Review 10.  Role of P2X7 and P2Y2 receptors on α-secretase-dependent APP processing: Control of amyloid plaques formation "in vivo" by P2X7 receptor.

Authors:  M Teresa Miras-Portugal; Juan I Diaz-Hernandez; Rosa Gomez-Villafuertes; Miguel Diaz-Hernandez; Antonio R Artalejo; Javier Gualix
Journal:  Comput Struct Biotechnol J       Date:  2015-03-11       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.